Abstract: Temperature-stable, gastric-resistant formulation suitable for oral and sustained delivery of proteins, including insulin, and for nucleic acids (e.g., DNA, RNA), and related methods of making and use are described. In an embodiment, The thermostable and acid-stable pharmaceutical composition includes an inclusion complex, where the inclusion complex includes a lipophilic active pharmaceutical ingredient-carrier ionic association complex encapsulated in a ?-cyclodextrin or derivative thereof. In an embodiment, the pharmaceutical composition ion-pair complex encapsulated in the ?-cyclodextrin or derivative thereof is in the form of a convenient dissolvable tablet dosage form.

Abstract: Multinuclear platinum compounds, compositions that include the platinum compounds, methods for making the platinum compounds, and methods for treating cellular proliferative diseases by administering the platinum compounds.

Abstract: Platinum compounds, pharmaceutically acceptable salts, and prodrugs thereof. Compositions that include the platinum compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier. Methods for using the platinum compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases.

Abstract: Multinuclear platinum compounds, compositions that include the platinum compounds, methods for making the platinum compounds, and methods for treating cellular proliferative diseases by administering the platinum compounds.

Abstract: Fluorinated compounds and emulsions including the compounds. The compositions are useful as oxygen carriers and surfactants. In one embodiment, the fluorinated compound is pH sensitive. In one embodiment, the fluorinated compound is a vitamin E derivative. In one embodiment, the fluorinated compound is a vitamin K derivative.

Abstract: Platinum carboxylate anticancer compounds, pharmaceutical compositions that include the platinum carboxylate compounds, and methods for treating cellular proliferative diseases by administering the platinum carboxylate compounds.

Abstract: Fluorinated compounds and emulsions including the compounds. The compositions are useful as oxygen carriers and surfactants. In one embodiment, the fluorinated compound is pH sensitive. In one embodiment, the fluorinated compound is a vitamin E derivative. In one embodiment, the fluorinated compound is a vitamin K derivative.

Abstract: Platinum compounds, pharmaceutically acceptable salts, and prodrugs thereof. Compositions that include the platinum compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier. Methods for using the platinum compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases.

Abstract: Platinum compounds, pharmaceutically acceptable salts, and prodrugs thereof. Compositions that include the platinum compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier. Methods for using the platinum compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases.

Abstract: Platinum carboxylate anticancer compounds, pharmaceutical compositions that include the platinum carboxylate compounds, and methods for treating cellular proliferative diseases by administering the platinum carboxylate compounds.

Abstract: Metformin salts of lipophilic acids, their pharmaceutical formulations, and methods of administrating the metformin salts for the treatment of hyperglycemia.

Abstract: Fluorinated compounds and emulsions including the compounds. The compositions are useful as oxygen carriers and surfactants. In one embodiment, the fluorinated compound is pH sensitive. In one embodiment, the fluorinated compound is a vitamin E derivative. In one embodiment, the fluorinated compound is a vitamin K derivative.

Abstract: Vitamin E conjugates, methods for their preparation, and compositions that include the conjugates. The vitamin E conjugates include a tocopherol moiety covalently coupled through a linker moiety to either a pyroglutamate moiety, a pyrrolidinone moiety, or a gentisic acid moiety.

Abstract: Platinum compounds, pharmaceutically acceptable salts, and prodrugs thereof. Compositions that include the platinum compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier. Methods for using the platinum compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases.

Abstract: Tocopherol derivatives are provided. In one embodiment, the tocopherol derivative includes a tocopherol moiety covalently coupled to branched hydrophilic moiety. In another embodiment, the tocopherol derivative includes a first tocopherol moiety covalently coupled to a second tocopherol moiety through a hydrophilic moiety. In other embodiments, the derivative includes three or more tocopherol moieties.

Abstract: Metformin salts of lipophilic acids, their pharmaceutical formulations, and methods of administrating the metformin salts for the treatment of hyperglycemia.

Abstract: Tocopherol derivatives are provided. In one embodiment, the tocopherol derivative includes a tocopherol moiety covalently coupled to branched hydrophilic moiety. In another embodiment, the tocopherol derivative includes a first tocopherol moiety covalently coupled to a second tocopherol moiety through a hydrophilic moiety. In other embodiments, the derivative includes three or more tocopherol moieties.